LOGIN  |  REGISTER
Cue Biopharma
Assertio

AirSculpt® Technologies Announces Opening of Its Newest Location in Raleigh

September 18, 2023 | Last Trade: US$4.75 0.06 1.28

MIAMI BEACH, Fla., Sept. 18, 2023 (GLOBE NEWSWIRE) -- AirSculpt® Technologies, Inc. (“AirSculpt”) (NASDAQ: AIRS), an industry leader and provider of premium body contouring procedures, today announced the opening of its newest center in Raleigh, NC. The Raleigh location increases the company’s center count to 27 locations throughout the United States, Canada and the UK.

AirSculpt® is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt locations. The minimally invasive procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results.

“We are thrilled to bring AirSculpt to Raleigh,” said Todd Magazine, Chief Executive Officer at AirSculpt® Technologies. “Our Charlotte location has delivered great results for North Carolinians so we are pleased to be able to deliver more location choices for potential patients.”

The Raleigh location is conveniently located in a prime spot between downtown Raleigh and Durham. The new office is located at 8510 Colonnade Center Drive, Suite 100, Raleigh, NC and can be reached at (919) 391-3750.

More than 40,000 AirSculpt cases have been performed in AirSculpt’s premium locations throughout the U.S, Canada and the United Kingdom. For additional information about scheduling a virtual or in-person consultation at any of the 27 centers, visit airsculpt.com.

About AirSculpt®

AirSculpt® is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results.

Investor Contact:
Steven Halper/Caroline Paul
Managing Directors, LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Stephanie Evans Greene
Chief Marketing Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB